Products to Fight HCV Infection
The Company is targeting the multi-billion dollar global hepatitis C market. The combined ribavirin and interferon market for treating hepatitis infection exceeds $4 Billion annually. The Company will gain regulatory approval, market and sell our own brands of ribavirin and pegylated-interferon-alpha. C-Pharma plans to complete the VLP vaccine Phase I safety and immunology study and then be in position to out-license this prophylactic vaccine indication to a major vaccine company focused on preventative vaccines.
\The Company will continue to advance the development of other anti-viral pipeline products and we plan to begin Phase II efficacy studies of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection. An antibody product derived from healthy volunteers administered VLP vaccine inoculations will be evaluated as a passive immunotherapy product in patients undergoing liver transplantation to prevent or significantly delay the liver graft re-infection by the hepatitis C virus.
(Read more...)
Ongoing collaborations with some of the world's leading hepatologists and hepatitis researchers will provide a steady stream of new, patented and proprietary products to expand the Company's liver-oriented product pipeline. |
|
The Company is now preparing to commercialize
the following products:
-
C-Virin – is a convenient, once-a-day oral formulation of ribavirin USP
.  - C-Pegferon –is our brand of long-lasting, pegylated-interferon-alpha-2b. This product and C-Virin will be used together for the treatment of genotype 1, 2, 3, and 4 strains of hepatitis C virus.
-
C-Vaxin – is a bivalent VLP vaccine and adjuvant combination designed to be used for the prevention of genotype-1 HCV infections or as an active-specific immunotherapy of chronic HCV disease
.  - C-Immune – is a genotype-1-specific human immune globulin (antibody) product made by donor plasma fractionation, used for passive immunotherapy of HCV patients who fail to respond to ribavirin and interferon, and will be developed for the prevention or delay of graft re-infection by HCV in liver transplant recipients whose livers have failed due to chronic HCV infection.
|
|
